← Back to Search

Blood Product

Blood Transfusion Strategies for Heart Attack Patients with Anemia (MINT Trial)

Phase 3

Waitlist Available

Led By Maria Mori Brooks, PhD

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 30 days of randomization

Awards & highlights

MINT Trial Summary

This trial compares two transfusion strategies for people with anemia who have had a heart attack.

Who is the study for?

This trial is for adults over 18 with acute myocardial infarction (heart attack) and anemia, who have a hemoglobin level below 10 g/dL. It's not suitable for those with uncontrolled bleeding, scheduled cardiac surgery, or in another conflicting study. Patients must be able to follow up after 30 days.Check my eligibility

What is being tested?

The study compares two red blood cell transfusion strategies—liberal vs restrictive—in treating patients with heart attacks who are also anemic. The goal is to determine which approach is more beneficial.See study design

What are the potential side effects?

Potential side effects of blood transfusions may include allergic reactions, fever, iron overload, lung injury from fluid overload, and rarely infectious disease transmission.

MINT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 30 days of randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 30 days of randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 30 days of randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Composite outcome of all-cause mortality or nonfatal myocardial reinfarction

Secondary outcome measures

Ischemia

Myocardial reinfarction

Other outcome measures

All-cause mortality

Hemorrhage

Blood stream infection

+12 more

MINT Trial Design

2Treatment groups

Active Control

Group I: Liberal Transfusion StrategyActive Control1 Intervention

Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.

Group II: Restrictive Transfusion StrategyActive Control1 Intervention

Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor

429 Previous Clinical Trials

60,726 Total Patients Enrolled

2 Trials studying Anemia

2,508 Patients Enrolled for Anemia

University of PittsburghOTHER

1,720 Previous Clinical Trials

16,339,305 Total Patients Enrolled

1 Trials studying Anemia

270 Patients Enrolled for Anemia

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,836 Previous Clinical Trials

47,307,606 Total Patients Enrolled

101 Trials studying Anemia

14,788 Patients Enrolled for Anemia

Media Library

Red Blood Cell Transfusion (Blood Product) Clinical Trial Eligibility Overview. Trial Name: NCT02981407 — Phase 3

Anemia Research Study Groups: Liberal Transfusion Strategy, Restrictive Transfusion Strategy

Anemia Clinical Trial 2023: Red Blood Cell Transfusion Highlights & Side Effects. Trial Name: NCT02981407 — Phase 3

Red Blood Cell Transfusion (Blood Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02981407 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current openings for this clinical trial?

"The clinical trial is still recruiting patients, according to the information on clinicaltrials.gov. This study was originally posted on April 25th, 2017, and the most recent update was on May 3rd, 2022."

Answered by AI

Do numerous hospitals in North America administer this trial?

"Patients are currently being accepted at this clinical trial's 78 locations, which include the Alexian Brothers Medical Center in Elk Grove Village, Illinois, University of Chicago Medical Center in Chicago, Minnesota, and Mayo Clinic in Rochester, Michigan."

Answered by AI

Does the Liberal Transfusion Strategy have FDA approval in the United States?

"Liberal Transfusion Strategy has been given a 3 for safety. This is because it is a Phase 3 trial, meaning that not only is there some data supporting efficacy, but multiple rounds of data also support safety."

Answered by AI

How many people are included in this clinical trial?

"This study needs 3,500 participants that adhere to the set inclusion criteria. People can take part in this research from locations such as Alexian Brothers Medical Center and University of Chicago Medical Center."

Answered by AI